Editas Medicine, Inc. 8EM.F Stock
Editas Medicine, Inc. Price Chart
Editas Medicine, Inc. 8EM.F Financial and Trading Overview
| Editas Medicine, Inc. stock price | 5.03 EUR |
| Previous Close | 9.47 EUR |
| Open | 8.39 EUR |
| Bid | 8.63 EUR x N/A |
| Ask | 8.74 EUR x N/A |
| Day's Range | 8.39 - 8.39 EUR |
| 52 Week Range | 5.75 - 18.88 EUR |
| Volume | 1K EUR |
| Avg. Volume | 65 EUR |
| Market Cap | 578.87M EUR |
| Beta (5Y Monthly) | 1.834859 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.9 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 54.77 EUR |
8EM.F Valuation Measures
| Enterprise Value | 353.25M EUR |
| Trailing P/E | N/A |
| Forward P/E | -2.3903134 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 25.398083 |
| Price/Book (mrq) | 1.7707895 |
| Enterprise Value/Revenue | 15.499 |
| Enterprise Value/EBITDA | -1.607 |
Trading Information
Editas Medicine, Inc. Stock Price History
| Beta (5Y Monthly) | 1.834859 |
| 52-Week Change | 11.09% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 18.88 EUR |
| 52 Week Low | 5.75 EUR |
| 50-Day Moving Average | 7.84 EUR |
| 200-Day Moving Average | 9.8 EUR |
8EM.F Share Statistics
| Avg. Volume (3 month) | 65 EUR |
| Avg. Daily Volume (10-Days) | 80 EUR |
| Shares Outstanding | 69M |
| Float | 66.77M |
| Short Ratio | N/A |
| % Held by Insiders | 0.36% |
| % Held by Institutions | 81.44% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -992.28% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -26.0020% |
| Return on Equity (ttm) | -52.74% |
Income Statement
| Revenue (ttm) | 22.79M EUR |
| Revenue Per Share (ttm) | 0.33 EUR |
| Quarterly Revenue Growth (yoy) | 45.50% |
| Gross Profit (ttm) | -155246000 EUR |
| EBITDA | -219838000 EUR |
| Net Income Avi to Common (ttm) | -218952992 EUR |
| Diluted EPS (ttm) | -3.44 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 318.44M EUR |
| Total Cash Per Share (mrq) | 4.75 EUR |
| Total Debt (mrq) | 37.14M EUR |
| Total Debt/Equity (mrq) | 11.7 EUR |
| Current Ratio (mrq) | 5.677 |
| Book Value Per Share (mrq) | 4.738 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -163890000 EUR |
| Levered Free Cash Flow (ttm) | -91186624 EUR |
Profile of Editas Medicine, Inc.
| Country | Germany |
| State | MA |
| City | Cambridge |
| Address | 11 Hurley Street |
| ZIP | 02141 |
| Phone | 617 401 9000 |
| Website | https://www.editasmedicine.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 226 |
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Q&A For Editas Medicine, Inc. Stock
What is a current 8EM.F stock price?
Editas Medicine, Inc. 8EM.F stock price today per share is 5.03 EUR.
How to purchase Editas Medicine, Inc. stock?
You can buy 8EM.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Editas Medicine, Inc.?
The stock symbol or ticker of Editas Medicine, Inc. is 8EM.F.
Which industry does the Editas Medicine, Inc. company belong to?
The Editas Medicine, Inc. industry is Biotechnology.
How many shares does Editas Medicine, Inc. have in circulation?
The max supply of Editas Medicine, Inc. shares is 82.24M.
What is Editas Medicine, Inc. Price to Earnings Ratio (PE Ratio)?
Editas Medicine, Inc. PE Ratio is now.
What was Editas Medicine, Inc. earnings per share over the trailing 12 months (TTM)?
Editas Medicine, Inc. EPS is -1.9 EUR over the trailing 12 months.
Which sector does the Editas Medicine, Inc. company belong to?
The Editas Medicine, Inc. sector is Healthcare.